← Leaderboards
Renata Ferrarotto
University Of Tx Md Anderson Can Ctr
$694,575
Attributed
$1,065,150
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $370.6K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,065,150 · 2
By mechanism
R01$741,150 · 1
R03$324,000 · 1
Top collaborators
- Simon Heeke2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Anil K Sood$29,572,737
- Michael J Galko$9,739,468
- Lauren Averett Byers$9,117,683
- John V. Heymach$11,138,593
- Florencia McAllister$3,653,632
Others in their field
Other Rising Stars on “Mutation”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Sabrina Paganoni · Massachusetts General Hospital$19,118,191
- Suma Babu · Massachusetts General Hospital$19,118,191
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Jinsy Andrews · Columbia University Health Sciences$9,819,674
- Frank A Provenzano · St. Joseph'S Hospital And Medical Center$8,533,907
Research focus
MutationSalivary GlandsGlandMolecular SubtypesProteogenomicsResponseCohortGenetic TranscriptionHeterogeneityMalignant NeoplasmsPrognosisBloodRecurrenceBlood SpecimenAdenoid Cystic CarcinomaClinical TrialsGene ExpressionGenesBiologicalHead And Neck CancerBiological MarkersLocal TherapyNotch1 GeneStandard Of Care
Grant awards (4)
Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic Carcinoma$370,575
R01 · FY2025 · CA · contact PI
Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic Carcinoma$370,575
R01 · FY2024 · CA · contact PI
Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic Carcinoma$162,000
R03 · FY2023 · DE · contact PI
Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic Carcinoma$162,000
R03 · FY2022 · DE · contact PI